Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

KYTX

Kyverna Therapeutics (KYTX)

Kyverna Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:KYTX
FechaHoraFuenteTítuloSímboloCompañía
17/06/202415:05PR Newswire (US)First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patient With Severe Stiff-Person Syndrome Published in Proceedings of the National Academy of Sciences (PNAS)NASDAQ:KYTXKyverna Therapeutics Inc
14/06/202405:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KYTXKyverna Therapeutics Inc
10/06/202417:56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KYTXKyverna Therapeutics Inc
10/06/202415:05PR Newswire (US)Kyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for Autoimmunity in Nature Reviews ImmunologyNASDAQ:KYTXKyverna Therapeutics Inc
07/06/202415:06PR Newswire (US)Kyverna Therapeutics to Present Data on 50 Patient Experience at Symposium at EULAR 2024NASDAQ:KYTXKyverna Therapeutics Inc
14/05/202415:29Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KYTXKyverna Therapeutics Inc
14/05/202415:05PR Newswire (US)Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial ResultsNASDAQ:KYTXKyverna Therapeutics Inc
11/04/202416:01PR Newswire (US)Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune DiseasesNASDAQ:KYTXKyverna Therapeutics Inc
29/03/202413:59PR Newswire (US)First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in MedNASDAQ:KYTXKyverna Therapeutics Inc
26/03/202415:05PR Newswire (US)Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial ResultsNASDAQ:KYTXKyverna Therapeutics Inc
07/03/202418:26PR Newswire (US)Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple SclerosisNASDAQ:KYTXKyverna Therapeutics Inc
12/02/202415:39PR Newswire (US)Kyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesNASDAQ:KYTXKyverna Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:KYTX